GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Castle Biosciences Inc (NAS:CSTL) » Definitions » Book Value per Share

CSTL (Castle Biosciences) Book Value per Share : $15.77 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Castle Biosciences Book Value per Share?

Castle Biosciences's book value per share for the quarter that ended in Sep. 2024 was $15.77.

During the past 12 months, Castle Biosciences's average Book Value Per Share Growth Rate was 9.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Castle Biosciences was 44.60% per year. The lowest was -5.20% per year. And the median was 19.70% per year.

Castle Biosciences's current price is $28.87. Its book value per share for the quarter that ended in Sep. 2024 was $15.77. Hence, today's PB Ratio of Castle Biosciences is 1.83.

During the past 7 years, the highest P/B Ratio of Castle Biosciences was 8.50. The lowest was 0.86. And the median was 2.07.


Castle Biosciences Book Value per Share Historical Data

The historical data trend for Castle Biosciences's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Castle Biosciences Book Value per Share Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial 4.97 16.75 16.22 15.03 14.27

Castle Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.35 14.27 14.59 15.30 15.77

Competitive Comparison of Castle Biosciences's Book Value per Share

For the Diagnostics & Research subindustry, Castle Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Castle Biosciences's PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Castle Biosciences's PB Ratio falls into.



Castle Biosciences Book Value per Share Calculation

Castle Biosciences's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(391.3-0.0)/27.4
=14.27

Castle Biosciences's Book Value Per Share for the quarter that ended in Sep. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(441.1-0.0)/28.0
=15.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Castle Biosciences  (NAS:CSTL) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Castle Biosciences Book Value per Share Related Terms

Thank you for viewing the detailed overview of Castle Biosciences's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Castle Biosciences Business Description

Traded in Other Exchanges
N/A
Address
505 South Friendswood Drive, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Executives
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Frank Stokes officer: Chief Financial Officer C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Derek J Maetzold director, 10 percent owner, officer: Pres. & Chief Exec. Officer 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Tobin W Juvenal officer: Chief Commercial Officer C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Kristen M Oelschlager officer: Chief Operating Officer C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Ellen Goldberg director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Tiffany Olson director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Bernhard E. Spiess officer: Chief Operating Officer C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Kim Caple director C/O BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
David S Kabakoff director, 10 percent owner C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Cook Joseph C. Iii director, 10 percent owner C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, STE. 201, FRIENDSWOOD TX 77546
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Bonnie H Anderson director 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mgc Venture Partners 2013 Gp, Llc 10 percent owner C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203
Mgc Venture Partners 2013, L.p. 10 percent owner C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203